Clinically Annotated Human Melanoma for TMEN Research

用于 TMEN 研究的临床注释人类黑色素瘤

• 批准号: 8555328
• 负责人: KEITH T FLAHERTY
• 金额: $ 16.56万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8555328
• 关键词: Antibodies; BRAF gene; Biopsy; Cells; Clinical; Clinical trial protocol document; Dana-Farber Cancer Institute; Endothelial Cells; Fibroblasts; Gene Mutation; Genotype; Goals; Human; Immune; MEKs; Malignant Neoplasms; Melanoma Cell; Mutation; PTEN gene; Patients; Pericytes; Phenotype; Point Mutation; Principal Investigator; Research; Research Infrastructure; Resistance; Role; Specimen; Therapeutic; Time; Tumor Suppressor Genes; cancer type; clinical infrastructure; experience; immunoregulation; inhibitor/antagonist; insight; melanoma; neoplastic cell; novel therapeutics; repository; response; tumor

Dr. Flaherty has been the principal investigator of the first combination targeted therapy trial to build on single agent BRAF inhibition in which a selective MEK inhibitor is combined with this agent. In addition to being the academic architect of these clinical trial protocols, Dr. Flaherty and colleagues at DF/HCC have accrued the largest number of patients to these trials. As a consequence, our center not only has the longest clinical experience with these agents, but also an increasingly large repository of archival tumor specimens and fresh tumor biopsies obtained before and during treatment, as well as at the time of clinical progression. This Core will continue to collect tumor biopsies prior to and during treatment with BRAF inhibitors, and then identify and isolate cellular constituents of the tumor microenvironment including immune subpopulations, endothelial cells, pericytes, and fibroblasts. We will also genetically characterize tumor cells for previously described oncogene and tumor suppressor gene alterations including point mutations and copy number. Our group is uniquely poised to direct our clinical and research infrastructure to studying the problem of resistance to BRAF targeted therapy.

Flaherty博士一直是针对性的第一个组合的主要研究者 以单位代理BRAF抑制为基础的治疗试验，其中选择性MEK抑制剂与此结合 代理人。除了成为这些临床试验方案的学术建筑师外，Flaherty博士及其同事 在DF/HCC处，这些试验的患者数量最多。结果，我们的中心不是 这些药物的临床经验最长，但也是越来越大的存储库 在治疗之前和期间获得的档案肿瘤标本和新鲜的肿瘤活检 临床进展的时间。该核心将在治疗前后继续收集肿瘤活检 使用BRAF抑制剂，然后识别和分离肿瘤微环境的细胞成分 包括免疫亚群，内皮细胞，周细胞和成纤维细胞。我们还将从基因上 表征先前描述的肿瘤细胞的肿瘤细胞和肿瘤抑制基因的改变，包括 点突变和拷贝数。我们的小组独特地指导我们的临床和研究 研究对BRAF靶向治疗的耐药性问题的基础设施。